FGFR3 and TP53 Gene Mutations Define Two Distinct Pathways in Urothelial Cell Carcinoma of the Bladder

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8108-8112

  Bakkar, Ashraf A ^a   Wallerand, Herve ^a   Radvanyi, François ^c   Lahaye, Jean Baptiste ^a   Pissard, Serge ^b   Lecerf, Laure ^a   Kouyoumdjian, Jean Claude ^b   Abbou, Claude C ^a   Pairon, Jean Claude ^a   Jaurand, Marie Claude ^a   Thiery, Jean Paul ^c   Chopin, Dominique K ^a   Diez De Medina, Sixtina Gil ^a  

^a INSERM   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53;

AMINO ACID SUBSTITUTION; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CARCINOMA IN SITU; CODON; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR CLASSIFICATION; UROTHELIAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; URINARY BLADDER NEOPLASMS;

EID: 10744222289     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lee, R., and Droller, M. J. The natural history of bladder cancer. Implications for therapy. Urol. Clin. N. Am., 27: 1-13, vii., 2000.
2. Knowles, M. A. The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int., 84: 412-427, 1999.
3. Fujimoto, K., Yamada, Y., Okajima, E., Kakizoe, T., Sasaki, H., Sugimura, T., and Terada, M. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res., 52: 1393-1398, 1992.
4. Olumi, A. F. A critical analysis of the use of p53 as a marker for management of bladder cancer. Urol. Clin. N. Am., 27: 75-82, ix, 2000.
5. Spruck, C. H., 3rd, Ohneseit, P. F., Gonzalez-Zulueta, M., Esrig, D., Miyao, N., Tsai, Y. C., Lerner, S. P., Schmutte, C., Yang, A. S., Cote, R., Dubeau, L., Nicolas, P. W., Hermann, G. G., Steven, K., Horn, T., Skinner, D. G., and Jones, P. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54: 784-788, 1994.
6. Johnson, D. E., and Williams, L. T. Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res., 60: 1-41, 1993.
7. Basilico, C., and Moscatelli, D. The FGF family of growth factors and oncogenes. Adv. Cancer Res., 59: 115-165, 1992.
8. Mason, I. J. The ins and outs of fibroblast growth factors. Cell, 78: 547-552, 1994.
9. Perez-Castro, A. V., Wilson, J., and Altherr, M. R. Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene. Genomics, 41: 10-16, 1997.
10. Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., and Radvanyi, F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet., 23: 18-20, 1999.
11. Webster, M. K., and Donoghue, D. J. Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain. Mol. Cell. Biol., 17: 5739-5747, 1997.
12. Li, C., Chen, L., Iwata, T., Kitagawa, M., Fu, X. Y., and Deng, C. X. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum. Mol. Genet., 8: 35-44, 1999.
13. Sibley, K., Cuthbert-Heavens, D., and Knowles, M. A. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene, 20: 686-691, 2001.
14. F. K. Mostofi, L. H. Sobin, and H. Torloni, (eds.), International Histological Classification of Tumors, No 10: Histological Typing of Urinary Bladder Tumors. Geneva: WHO, 1973.
15. Sobin, L. H., and Fleming, I. D. TNM Classification of Malignant Tumors, Ed. 5 (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer (Phila.), 80: 1803-1804, 1997.
16. Cappellen, D., Gil Diez de Medina, S., Chopin, D., Thiery, J. P., and Radvanyi, F. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene, 14: 3059-3066, 1997.
17. Jones, A. C., Austin, J., Hansen, N., Hoogendoorn, B., Oefner, P. J., Cheadle, J. P., and O'Donovan M. C. Optimal temperature selection for mutation detection by Denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. Clin. Chem., 45: 1133-1140, 1999.
18. Billerey, C., Chopin, D., Aubriot-Lorton, M. H., Ricol, D., Gil Diez de Medina, S., Van Rhijn, B., Bralet, M. P., Lefrere-Belda, M. A., Lahaye, J. B., Abbou, C. C., Bonaventure, J., Zafrani, E. S., van der Kwast, T., Thiery, J. P., and Radvanyi, F. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol., 158: 1955-1959, 2001.
19. van Rhijn, B. W., Lurkin, I., Radvanyi, F., Kirkels, W. J., van der Kwast, T. H., and Zwarthoff, E. C. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res., 61: 1265-1268, 2001.
20. Cordon-Cardo, C., Cote, R. J., and Sauter, G. Genetic and molecular markers of urothelial premalignancy and malignancy. Scand J. Urol. Nephrol., 205(Suppl.): 82-93, 2000.
21. Hainaut, P., and Hollstein, M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res., 77: 81-137, 2000.
22. Van Rhijn, B. W., Montironi, R., Zwarthoff, E. C., Jobsis, A. C., and Van Der Kwast, T. H. Frequent FGFR3 mutations in urothelial papilloma. J. Pathol., 198: 245-251, 2002.
23. Richter, J., Jiang, F., Gorog, J. P., Sartorius, G., Egenter, C., Gasser, T. C., Moch, H., Mihatsch, M. J., and Sauter, G. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res., 57: 2860-2864, 1997.
24. Primdahl, H., Wikman, F. P., von der Maase, H., Zhou, X. G., Wolf, H., and Orntoft, T. F. Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. J. Natl. Cancer Inst., 94: 216-223, 2002.
25. Moll, U. M., and Schramm, L. M. p53 - an acrobat in tumorigenesis. Crit. Rev. Oral. Biol. Med., 9: 23-37, 1998.